DGOS

DGOS is a biotechnology company focused on the development of glycan-based therapeutics through its proprietary Directed Glycan Orchestration System (DGOS) platform. The company specializes in addressing complex diseases related to glycosylation, including rare congenital disorders and certain types of cancer. By leveraging advanced chemical and enzymatic synthesis, DGOS aims to create precisely engineered glycans that can modulate biological pathways with high specificity. The company's approach combines deep expertise in glycobiology with innovative drug discovery techniques to target previously undruggable pathways. DGOS is currently in the pre-clinical stage, advancing a pipeline of candidates designed to restore or modify glycan function in patients.